Authorized purpose: Case-level triage of adult non-contrast head CT examinations with features suggestive of intracranial hemorrhage (ICH); not a diagnostic or rule-out tool.
Clinical role
Parallel case-level triage and notification support; standard-of-care review remains required and cases are not removed from the worklist.
Images and patients
CT/CTA · Head/brain
Key limitation
Keep in mind: Indicated only for adults and suspected ICH on non-contrast head CT. It does not address anomalies other than ICH, direct attention to an image location, make standalone clinical decisions, rule out hemorrhage, or preclude clinical assessment.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Case-level triage of adult non-contrast head CT examinations with features suggestive of intracranial hemorrhage (ICH); not a diagnostic or rule-out tool.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Head/brain Input: DICOM adult non-contrast head CT studies; input validation checks age, modality, and view compatibility.
Who uses it?Intended users: Radiologists and other qualified medical staff who regularly read head CT scans
What does the software produce?Output: A case-level suspected-ICH notification is sent through the Zebra Imaging Analytics Platform to a PACS/workstation for worklist prioritization; no image, marking, or highlighted location is output.
What is its most important limitation?Key limitation: Indicated only for adults and suspected ICH on non-contrast head CT. It does not address anomalies other than ICH, direct attention to an image location, make standalone clinical decisions, rule out hemorrhage, or preclude clinical assessment.
Clinical takeaway. Clinical role: Case-level triage of adult non-contrast head CT examinations with features suggestive of intracranial hemorrhage (ICH); not a diagnostic or rule-out tool.
Evidence takeaway. Evidence from the reviewed source record: Retrospective stand-alone validation used 427 anonymized head CT cases from the USA and Israel (199 ICH-positive and 228 negative), ages 18-102, truthed by two US board-certified neuroradiologists with a third senior neuroradiologist for disagreement. FDA reported sensitivity 94.47% (95% CI: 90.32%-97.21%), specificity 92.54% (95% CI: 88.33%-95.60%), overall agreement 93% (95% CI: 90.66-95.60), and mean per-case processing time 48.67 seconds (95% CI: 47.06-50.28).
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Case-level triage of adult non-contrast head CT examinations with features suggestive of intracranial hemorrhage (ICH); not a diagnostic or rule-out tool.
A case-level suspected-ICH notification is sent through the Zebra Imaging Analytics Platform to a PACS/workstation for worklist prioritization; no image, marking, or highlighted location is output.
Indicated only for adults and suspected ICH on non-contrast head CT. It does not address anomalies other than ICH, direct attention to an image location, make standalone clinical decisions, rule out hemorrhage, or preclude clinical assessment.
Retrospective stand-alone validation used 427 anonymized head CT cases from the USA and Israel (199 ICH-positive and 228 negative), ages 18-102, truthed by two US board-certified neuroradiologists with a third senior neuroradiologist for disagreement. FDA reported sensitivity 94.47% (95% CI: 90.32%-97.21%), specificity 92.54% (95% CI: 88.33%-95.60%), overall agreement 93% (95% CI: 90.66-95.60), and mean per-case processing time 48.67 seconds (95% CI: 47.06-50.28).
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Retrospective stand-alone validation used 427 anonymized head CT cases from the USA and Israel (199 ICH-positive and 228 negative), ages 18-102, truthed by two US board-certified neuroradiologists with a third senior neuroradiologist for disagreement. FDA reported sensitivity 94.47% (95% CI: 90.32%-97.21%), specificity 92.54% (95% CI: 88.33%-95.60%), overall agreement 93% (95% CI: 90.66-95.60), and mean per-case processing time 48.67 seconds (95% CI: 47.06-50.28).
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
HealthICH regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K190424
Samplen=427
IndependenceIndependence not established
K190424
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K190424. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM adult non-contrast head CT studies; input validation checks age, modality, and view compatibility.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: After a head CT, a copy of the study is automatically retrieved and processed; HealthICH returns the notification to the Zebra Imaging Analytics Platform, which distributes it to the PACS/workstation through the worklist interface. The packet identifies DICOM images but does not establish a specific local PACS interface.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-11-14 ·
Returned objects
Source context, not route validation: A case-level suspected-ICH notification is sent through the Zebra Imaging Analytics Platform to a PACS/workstation for worklist prioritization; no image, marking, or highlighted location is output.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: A case-level suspected-ICH notification is sent through the Zebra Imaging Analytics Platform to a PACS/workstation for worklist prioritization; no image, marking, or highlighted location is output.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
After a head CT, a copy of the study is automatically retrieved and processed; HealthICH returns the notification to the Zebra Imaging Analytics Platform, which distributes it to the PACS/workstation through the worklist interface. The packet identifies DICOM images but does not establish a specific local PACS interface.
The 510(k) summary states HealthICH is intended for use by radiologists and other qualified medical staff who read head CT scans on a regular basis, and that the final diagnosis is provided by a radiologist or other qualified physician after examining the original scan as determined by the clinical standard of care.
Exact FDA submission
Checked 2026-10-27
User qualification wording only; the summary specifies no training program or training offering for this device.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
26Fields reviewed
9Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K190424 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission
The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-09 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Triage and notification of suspected intracranial hemorrhage on non-contrast head CT in adults and transitional adolescents aged 18 years and older, to assist prioritization while full images remain subject to standard-of-care interpretation.
Authorized purpose: Notification-only triage of adult non-contrast head CT for suspected intracranial hemorrhage and large-vessel occlusion, with parallel communication to trained clinicians during standard care.
Modality
CT/CTA
Anatomy
Brain and intracranial vessels: intracranial hemorrhage and LVO involving ICA, MCA-M1, and MCA-M2
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.